Barclays’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.5M | Sell |
1,890,100
-554,063
| -23% | -$3.79M | ﹤0.01% | 1249 |
|
|
2025
Q4 | $4.84M | Buy |
2,444,163
+1,516,476
| +163% | +$3.44M | ﹤0.01% | 2243 |
|
|
2025
Q3 | $2.28M | Buy |
927,687
+87,793
| +10% | +$226K | ﹤0.01% | 2797 |
|
|
2025
Q2 | $2.22M | Buy |
839,894
+474,859
| +130% | +$1.28M | ﹤0.01% | 2768 |
|
|
2025
Q1 | $1.1M | Sell |
365,035
-31,449
| -8% | -$95.3K | ﹤0.01% | 3049 |
|
|
2024
Q4 | $1.02M | Buy |
396,484
+35,448
| +10% | +$148K | ﹤0.01% | 3373 |
|
|
2024
Q3 | $1.34M | Buy |
361,036
+202,248
| +127% | +$936K | ﹤0.01% | 3152 |
|
|
2024
Q2 | $1M | Sell |
158,788
-226,881
| -59% | -$1.5M | ﹤0.01% | 2598 |
|
|
2024
Q1 | $2.07M | Sell |
385,669
-93,876
| -20% | -$425K | ﹤0.01% | 2543 |
|
|
2023
Q4 | $2.41M | Buy |
479,545
+435,172
| +981% | +$1.37M | ﹤0.01% | 2770 |
|
|
2023
Q3 | $75K | Sell |
44,373
-16,096
| -27% | -$32.3K | ﹤0.01% | 3698 |
|
|
2023
Q2 | $168K | Buy |
60,469
+19,181
| +46% | +$54.2K | ﹤0.01% | 3332 |
|
|
2023
Q1 | $75.1K | Sell |
41,288
-215,077
| -84% | -$669K | ﹤0.01% | 4318 |
|
|
2022
Q4 | $1.3M | Buy |
256,365
+3,335
| +1% | +$18.3K | ﹤0.01% | 2585 |
|
|
2022
Q3 | $1.26M | Buy |
253,030
+242,167
| +2,229% | +$1.1M | ﹤0.01% | 2057 |
|
|
2022
Q2 | $40K | Sell |
10,863
-778
| -7% | -$3.13K | ﹤0.01% | 4121 |
|
|
2022
Q1 | $66K | Buy |
+11,641
| New | +$71.4K | ﹤0.01% | 3983 |
|
|
2021
Q1 | – | Sell |
-37,686
| Closed | -$503K | – | 4929 |
|
|
2020
Q4 | $503K | Sell |
37,686
-18,316
| -33% | -$176K | ﹤0.01% | 3228 |
|
|
2020
Q3 | $388K | Buy |
56,002
+1,446
| +3% | +$14.4K | ﹤0.01% | 3418 |
|
|
2020
Q2 | $670K | Buy |
54,556
+54,516
| +136,290% | +$308K | ﹤0.01% | 3093 |
|
|
2020
Q1 | $0 | Sell |
40
-42
| -51% | -$210 | ﹤0.01% | 6277 |
|
|
2019
Q4 | $0 | Hold |
82
| – | – | ﹤0.01% | 6548 |
|
|
2019
Q3 | $0 | Sell |
82
-2,062
| -96% | -$2.56K | ﹤0.01% | 6883 |
|
|
2019
Q2 | $3K | Sell |
2,144
-6,629
| -76% | -$7.65K | ﹤0.01% | 6759 |
|
|
2019
Q1 | $14K | Buy |
8,773
+7,814
| +815% | +$9.81K | ﹤0.01% | 6464 |
|
|
2018
Q4 | $1K | Sell |
959
-10,481
| -92% | -$24K | ﹤0.01% | 6802 |
|
|
2018
Q3 | $42K | Buy |
11,440
+9,332
| +443% | +$29.5K | ﹤0.01% | 6173 |
|
|
2018
Q2 | $6K | Sell |
2,108
-11,439
| -84% | -$42.4K | ﹤0.01% | 6673 |
|
|
2018
Q1 | $52K | Sell |
13,547
-14,539
| -52% | -$63.8K | ﹤0.01% | 5874 |
|
|
2017
Q4 | $126K | Buy |
28,086
+1,584
| +6% | +$7.5K | ﹤0.01% | 5054 |
|
|
2017
Q3 | $145K | Buy |
26,502
+1,112
| +4% | +$6.85K | ﹤0.01% | 4666 |
|
|
2017
Q2 | $193K | Sell |
25,390
-60,967
| -71% | -$263K | ﹤0.01% | 4391 |
|
|
2017
Q1 | $306K | Buy |
86,357
+83,192
| +2,628% | +$411K | ﹤0.01% | 3900 |
|
|
2016
Q4 | $18K | Sell |
3,165
-594
| -16% | -$3.96K | ﹤0.01% | 5667 |
|
|
2016
Q3 | $30K | Buy |
3,759
+2,397
| +176% | +$17.9K | ﹤0.01% | 5267 |
|
|
2016
Q2 | $8K | Buy |
1,362
+801
| +143% | +$6.22K | ﹤0.01% | 5614 |
|
|
2016
Q1 | $4K | Sell |
561
-973
| -63% | -$9.17K | ﹤0.01% | 5715 |
|
|
2015
Q4 | $26K | Buy |
+1,534
| New | +$22.8K | ﹤0.01% | 5109 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Barclays's IBRX Position: Q1 2026 in Review
Barclays reduced its ImmunityBio (IBRX) stake by 23% in Q1 2026, selling an estimated $3.79M and leaving 1,890,100 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1249.
Barclays first reported a position in IBRX in Q4 2015 and has held it in 38 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Barclays held 1,890,100 shares of ImmunityBio worth $14.5M as of Q1 2026.
- Barclays sold 554,063 ImmunityBio shares in Q1 2026, an estimated $3.79M.
- ImmunityBio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1249 holding.
- Barclays first reported a position in ImmunityBio in Q4 2015 and has held it in 38 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.